Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT02765594
- Locations
- 🇨🇳
Peing Union Medical College Hospital, Beijing, China
Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation
- Conditions
- Interventions
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 118
- Registration Number
- NCT02687932
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Yonsei University Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Chronopharmacology of Valsartan in Normotensive Subjects
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 24
- Registration Number
- NCT02631031
- Locations
- 🇪🇬
Ain Shams university, Cairo, Egypt
Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients
- Conditions
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 1
- Registration Number
- NCT02606279
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Physiologic Interactions Between the Adrenal- and the Parathyroid Glands
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 81
- Registration Number
- NCT02572960
- Locations
- 🇩🇰
Department of Endocrinology and Internal Medicine, Aarhus, Denmark
Fimasartan Achieving SBP Target (FAST) Study
- Conditions
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 369
- Registration Number
- NCT02495324
- Locations
- 🇰🇷
The Catholic University of Korea,Uijeongbu St.Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea, St. Paul's Hospital, Seoul, Dongdaemun-gu, Korea, Republic of
🇰🇷The Catholic University of Korea, St.Vincent's Hospital., Suwon-si, Gyeonggi-do, Korea, Republic of
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 612
- Registration Number
- NCT02480764
- Locations
- 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Beijing Anzhen Hospital, Beijing, Beijing, China
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol
- Conditions
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 105
- Registration Number
- NCT02403349
Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02299310
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 440
- Registration Number
- NCT02242318
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.